PMID- 33922229
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220223
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 9
DP  - 2021 Apr 22
TI  - Plasminogen Activators in Neurovascular and Neurodegenerative Disorders.
LID - 10.3390/ijms22094380 [doi]
LID - 4380
AB  - The neurovascular unit (NVU) is a dynamic structure assembled by endothelial 
      cells surrounded by a basement membrane, pericytes, astrocytes, microglia and 
      neurons. A carefully coordinated interplay between these cellular and 
      non-cellular components is required to maintain normal neuronal function, and in 
      line with these observations, a growing body of evidence has linked NVU 
      dysfunction to neurodegeneration. Plasminogen activators catalyze the conversion 
      of the zymogen plasminogen into the two-chain protease plasmin, which in turn 
      triggers a plethora of physiological events including wound healing, 
      angiogenesis, cell migration and inflammation. The last four decades of research 
      have revealed that the two mammalian plasminogen activators, tissue-type 
      plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), are 
      pivotal regulators of NVU function during physiological and pathological 
      conditions. Here, we will review the most relevant data on their expression and 
      function in the NVU and their role in neurovascular and neurodegenerative 
      disorders.
FAU - Yepes, Manuel
AU  - Yepes M
AUID- ORCID: 0000-0002-5224-9663
AD  - Department of Neurology, Emory University, Atlanta, GA 30329, USA.
AD  - Neuropharmacology and Neurological Diseases Section, Yerkes National Primate 
      Research Center, Atlanta, GA 30329, USA.
AD  - Department of Neurology, Veterans Affairs Medical Center, Decatur, GA 30329, USA.
FAU - Woo, Yena
AU  - Woo Y
AUID- ORCID: 0000-0002-5853-9004
AD  - Neuropharmacology and Neurological Diseases Section, Yerkes National Primate 
      Research Center, Atlanta, GA 30329, USA.
FAU - Martin-Jimenez, Cynthia
AU  - Martin-Jimenez C
AD  - Neuropharmacology and Neurological Diseases Section, Yerkes National Primate 
      Research Center, Atlanta, GA 30329, USA.
LA  - eng
GR  - P51 OD011132/OD/NIH HHS/United States
GR  - NS091201/NH/NIH HHS/United States
GR  - I01BX003441/U.S. Department of Veterans Affairs/
PT  - Journal Article
PT  - Review
DEP - 20210422
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Receptors, Urokinase Plasminogen Activator)
RN  - EC 3.4.21.- (Plasminogen Activators)
SB  - IM
MH  - Animals
MH  - Cerebrovascular Disorders/metabolism/*pathology
MH  - Humans
MH  - Neurodegenerative Diseases/metabolism/*pathology
MH  - Plasminogen Activators/*metabolism
MH  - Receptors, Urokinase Plasminogen Activator/*metabolism
PMC - PMC8122722
OTO - NOTNLM
OT  - neurodegeneration
OT  - tissue-type plasminogen activator (tPA)
OT  - urokinase-type plasminogen activator (uPA)
COIS- The authors declare no conflict of interest.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/15 06:00
PMCR- 2021/04/22
CRDT- 2021/04/30 01:21
PHST- 2021/03/18 00:00 [received]
PHST- 2021/04/14 00:00 [revised]
PHST- 2021/04/20 00:00 [accepted]
PHST- 2021/04/30 01:21 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/04/22 00:00 [pmc-release]
AID - ijms22094380 [pii]
AID - ijms-22-04380 [pii]
AID - 10.3390/ijms22094380 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Apr 22;22(9):4380. doi: 10.3390/ijms22094380.